 According to the Barcelona clinic liver cancer BCLC staging treatment guideline, sorafenib is recommended for Hepatocellular Carcinoma HCC with Portal Vein Tumor Thrombosis PVTT, but HCC with major PVTT in the main trunk or 1st-order branches of the portal vein did not benefit much from sorafenib in previous studies. There is no established standard treatment for HCC patients with major PVTT, the investigators conducted a randomized, phase 2 study to investigate the survival benefit of sorafenib plus Hepatic arterial infusion chemotherapy HAIC with Oxaliplatin and Fluorouracil versus sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. 